|
|
|
|
| LEADER |
00000cam a22000007a 4500 |
| 001 |
SCIDIR_on1406595761 |
| 003 |
OCoLC |
| 005 |
20231120010757.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
231030s2023 xx o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d SFB
|d OPELS
|d OCLCO
|
| 020 |
|
|
|a 9780443133411
|q (electronic bk.)
|
| 020 |
|
|
|a 0443133417
|q (electronic bk.)
|
| 020 |
|
|
|z 9780443133404
|
| 020 |
|
|
|z 0443133409
|
| 035 |
|
|
|a (OCoLC)1406595761
|
| 050 |
|
4 |
|a RA1242.H35
|
| 082 |
0 |
4 |
|a 547
|
| 245 |
0 |
0 |
|a Neurotoxicity of halogenated organic compounds /
|c edited by Prasada Rao S. Kodavanti, Michael Aschner, Lucio G. Costa.
|
| 260 |
|
|
|a [S.l.] :
|b Academic Press,
|c 2023.
|
| 300 |
|
|
|a 1 online resource.
|
| 490 |
0 |
|
|a Advances in neurotoxicology ;
|v 10
|
| 505 |
0 |
|
|a Front Cover -- Advances in Neurotoxicology -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Perspective on halogenated organic compounds -- 1 Introduction -- 2 Background and classes of HOCs -- 2.1 Chlorinated HOCs -- 2.1.1 Physicochemical properties -- 2.1.2 Environmental contamination and exposure to humans -- 2.1.3 Effects on human health -- 2.2 Brominated HOCs -- 2.2.1 Physicochemical properties -- 2.2.2 Environmental contamination and human exposure -- 2.2.3 Effects on human health -- 2.3 Fluorinated HOCs -- 2.3.1 Physicochemical properties -- 2.3.2 Environmental contamination and human exposure -- 2.3.3 Effects on human health -- 3 Summary and conclusions -- Acknowledgments -- References -- Further reading -- Chapter Two: The neurotoxicity of polychlorinated biphenyls (PCBs) -- 1 Introduction -- 2 Human studies -- 2.1 Developmental neurotoxicity -- 2.1.1 Yu-Cheng studies -- 2.1.2 Michigan cohorts -- 2.1.3 Dutch cohort -- 2.1.4 German studies -- 2.1.5 Faroe Islands cohort -- 2.1.6 Oswego, New York cohort -- 2.1.7 The New Bedford, Massachusetts studies -- 2.1.8 Inuit cohort -- 2.1.9 Flemish environmental health survey -- 2.1.10 Rhea study, Crete, Greece -- 2.1.11 Norwegian study -- 2.1.12 The Collaborative Perinatal Project -- 2.2 PCBs as environmental risk factors for neurodevelopmental disorders (NDDs) -- 2.3 Data gaps in the human literature on PCB developmental neurotoxicity -- 2.4 Neurotoxic outcomes in adults -- 2.5 PCB effects on neurodegenerative diseases -- 3 Experimental animal studies -- 3.1 Learning and memory -- 3.2 Motor function -- 3.3 Attention -- 3.4 Social behavior -- 3.5 Insights from behavioral studies of mechanisms of PCB neurotoxicity -- 4 Conclusions -- Acknowledgments -- Declaration of competing interests -- References -- Chapter Three: Neuroendocrine effects of polychlorinated biphenyls (PCBs).
|
| 505 |
8 |
|
|a 1 Introduction -- 2 Overview of the hypothalamic-pituitary-gonadal and hypothalamic-pituitary-thyroid neuroendocrine systems -- 2.1 Hormones and hypothalamic development -- 2.2 Hypothalamic organization and differentiation -- 2.3 Hormone receptors and differentiation -- 2.4 The developmental origins of health and disease (DOHaD) hypothesis, and environmental epigenetics -- 2.5 Epigenetic programming -- 3 PCBs as environmental neuroendocrine disruptors -- 4 PCBs effects on the hypothalamic-pituitary-gonadal axis -- 4.1 Developmental exposures to PCBs: Effects on neuroendocrine systems -- 4.2 Behavioral effects of developmental PCB exposures -- 4.3 PCB effects on social behaviors -- 4.4 PCB effects on reproductive and sociosexual behaviors -- 4.5 PCB effects on anxiety and stress behaviors -- 4.6 Molecular and cellular effects of developmental PCB exposure on the hypothalamus -- 4.7 Human exposures to PCBs and neuroendocrine-related behaviors -- 5 PCBs and the hypothalamic-pituitary-thyroid axis -- 5.1 Background information on the thyroid system -- 5.1.1 Role of deiodinases and cellular transporters -- 5.1.2 The current model of the thyroid hormone system -- 5.2 Evidence that PCBs affect brain development by interfering with the thyroid hormone system -- 5.3 The effect of PCB exposures on human neurodevelopment -- 6 Neuroendocrine effects of PCBs on the hypothalamo-neurohypophysial system (HNS) -- 6.1 Organization of the HNS and its osmoregulatory function -- 6.2 PCB effects on the peripheral vasopressin system -- 6.2.1 PCB Effects on Vasopressin-Mediated Physiological Functions -- 6.2.1.1 Role of nitric oxide (NO) -- 6.3 PCB effects on the central vasopressin and oxytocin systems -- 7 Inter- and transgenerational effects of PCBs on neuroendocrine systems -- 7.1 Multigenerational A1221 effects: Neuroendocrine physiology and gene expression.
|
| 505 |
8 |
|
|a 7.2 Multigenerational PCB effects on behavior -- 7.2.1 Epigenetic mechanisms of PCBs -- 8 The future of toxicity testing for endocrine disruption: The ATHENA project on thyroid hormone system disruptors -- Acknowledgments -- References -- Chapter Four: Ryanodine receptor-dependent mechanisms of PCB developmental neurotoxicity -- 1 Introduction -- 2 PCB-RyR interactions -- 2.1 RyR structure and function -- 2.2 PCB sensitization of the RyR -- 3 RyR-dependent cellular effects of PCBs -- 3.1 Dendritic arborization and synaptogenesis -- 3.2 Neuronal apoptosis -- 4 Evidence that RyR sensitization mediates the behavioral effects of PCBs -- 4.1 Experimental animal studies -- 4.2 Human studies -- 5 Implications of RyR-dependent mechanisms of PCB developmental neurotoxicity -- 5.1 RyR sensitization as a convergent mechanism of PCB developmental neurotoxicity -- 5.2 Assessing PCB risks to the developing human brain -- 5.3 Identifying gene-environment interactions that influence NDD risk -- 6 Conclusions -- Acknowledgments -- Declaration of competing interests -- References -- Chapter Five: The microbiome/microbiota and the neurotoxicity of polybrominated diphenyl ether (PBDE) flame retardantsMicrobiome and PBDE neurotoxicity -- 1 PBDEs: Uses, contamination, and body burden -- 1.1 Uses -- 1.2 Contamination -- 1.3 Body burden -- 2 Kinetics of PBDEs and structure-activity relationship considerations -- 3 PBDEs: Adverse health effects -- 4 Neurotoxicity of PBDEs -- 5 Possible mechanisms of PBDE developmental neurotoxicity -- 5.1 Effects of PBDEs on thyroid hormones -- 5.2 PBDE-induced oxidative stress and consequent cell damage -- 5.3 Other proposed mechanisms -- 6 An overview of the microbiome and microbiota -- 7 PBDEs and the microbiota -- 7.1 Associations between PBDE exposure and fecal microbiota in humans.
|
| 505 |
8 |
|
|a 8 Effects of PBDEs on the microbiota and its association with neurotoxicity -- 8.1 Evidence from human fecal microbiome -- 8.2 Evidence from animal studies: Rodents -- 8.3 Evidence from animal studies: Zebrafish -- 9 Conclusions and future avenues for research -- Acknowledgments -- References -- Chapter Six: Neuroendocrine effects of brominated flame retardants, focused on polybrominated diphenyl ethersNeuroendocrine effects of brominated flame retardants -- 1 Introduction -- 2 General characteristics of the main BFRs -- 2.1 Polybrominated diphenyl ethers (PBDEs) -- 2.2 Polybrominated biphenyls (PBBs) -- 2.3 Hexabromocyclododecane (HBCD) -- 2.4 Tetrabromobisphenol A (TBBPA) -- 2.5 Novel brominated flame retardants (NBFRs) -- 3 Overview of the neuroendocrine system -- 4 Neuroendocrine disruption by BFRs -- 5 Neuroendocrine effects of PBDEs -- 5.1 PBDE effects on the HP-thyroid (HPT) axis -- 5.1.1 In vitro studies -- 5.1.2 Animal studies -- 5.1.3 Human studies -- 5.2 PBDE effects on the HP-gonadal (HPG) axis -- 5.2.1 In vitro studies -- 5.2.2 Animal studies -- 5.2.3 Human studies -- 5.3 PBDE effects on the HP-adrenal (HPA) axis -- 5.4 PBDE effects on the HP-somatotropic (HPS) axis -- 5.5 PBDE effects on the HN axis (oxytocin and arginine vasopressin) -- 6 Neuroendocrine effects of PBBs -- 6.1 PBB effects on the HPT axis -- 6.2 PBB effects on the HPG axis -- 6.3 PBB effects on the HPA axis -- 7 Neuroendocrine effects of HBCD -- 7.1 HBCD effects on the HPT axis -- 7.2 HBCD effects on the HPG axis -- 8 Neuroendocrine effects of TBBPA -- 8.1 TBBPA effects on the HPT axis -- 8.2 TBBPA effects on the HPG axis -- 9 Neuroendocrine effects of NBFRs -- 9.1 NBFR effects on the HPT axis -- 9.2 NBFR effects on the HPG axis -- 9.3 Metabolic disruption by NBFRs -- 10 General conclusions -- Acknowledgments -- References.
|
| 505 |
8 |
|
|a Chapter Seven: Neurochemical effects of halogenated organic compounds: Possible adverse outcome pathways and structure-activity relationshipsNeurochemical effects of halogenated organic compounds -- 1 Introduction -- 2 Human (epidemiological studies) evidence of neurotoxicity by HOCs (PCBs and PBDEs) -- 3 Evidence of neurotoxicity in animals by HOCs (PCBs and PBDEs) -- 4 Neurotoxicity of HOCs (PCBs and PBDEs)-Potential adverse outcome pathways -- 4.1 Perturbed calcium homeostasis and kinase signaling as a potential AOP for HOCs -- 4.1.1 HOC effects on free calcium ([Ca2+]i) levels -- 4.1.2 HOC effects on signal transduction pathways -- 4.1.3 HOC effects on PKC isoforms in vivo -- 4.1.4 HOC effects on genomic and proteomic changes in vivo -- 4.1.5 HOC effects on structural and functional changes in vivo -- 4.2 Perturbed thyroid hormone homeostasis as a potential AOP for HOCs -- 4.3 Altered neurotransmitters and their function as a potential AOP for HOCs -- 4.3.1 HOC effects on dopamine -- 4.3.2 HOC effects on serotonin -- 4.3.3 HOC effects on acetylcholine -- 4.4 Oxidative stress as a potential AOP for HOCs -- 5 Structure-activity relationships among HOCs (PCBs and PBDEs) on intracellular signaling events (PKC translocation and calcium buffering) -- 5.1 SAR based on number of halogens with mixtures and congeners -- 5.2 SAR based on position of halogens with HOC congeners -- 5.3 SAR of structurally related HOCs: Role of planarity in the activity of HOCs -- 5.4 SAR of structurally related HOCs: Similarities in the effects of PCBs and PBDEs -- 5.5 Interactive effects of environmentally relevant HOCs (ex., PCBs, PCB metabolites, and dioxins) -- 6 Summary and future directions -- Acknowledgments -- References -- Chapter Eight: Neurotoxicity of poly- and perfluoroalkyl substances (PFAS): Epidemiological and rodent studies of behavioral outcomes.
|
| 650 |
|
0 |
|a Organohalogen compounds
|x Toxicology.
|
| 650 |
|
0 |
|a Neurotoxicology.
|
| 650 |
|
6 |
|a Compos�es organohalog�en�es
|0 (CaQQLa)201-0011213
|x Toxicologie.
|0 (CaQQLa)201-0379898
|
| 650 |
|
6 |
|a Neurotoxicologie.
|0 (CaQQLa)201-0041644
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780443133411
|
| 776 |
0 |
8 |
|c Original
|z 0443133409
|z 9780443133404
|w (OCoLC)1370925234
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/24687480/10
|z Texto completo
|
